Capital Cell is Europe’s first equity crowdfunding platform specialised in life science.
|Telephone:||01223 967 184|
|Address:||25 Hill Street, London|
|Membership type:||Corporate 6-20 (£250+VAT pa)|
Capital Cell opens life science investment to everyone by sourcing the most innovative early-stage life science companies, and presenting them on a regulated online investment platform.
Capital Cell works with the highly innovative BioExpert Network and sophisticated lead investors to filter companies under review.
Capital Cell redefines life science investment, and funds projects that change lives.
Laura Ferguson has been recognised as one of the '50 Movers and Shakers of BioBusiness' for 2017 in recognition of the launch of Capital Cell UK.
8 November 2017Read in full
2015-16 saw a third consecutive year of venture capital financing growth in Medtech, with a record $5.6 billion raised globally (Ref: EY Medtech report 2016). European Medtech companies enjoyed 12% growth in financing in the same period.
31 October 2017Read in full
Investing in the UK’s innovative life sciences and biotech sector just became more accessible to a wide spectrum of investors, with Capital Cell, Europe’s first dedicated Life Sciences crowdfunding platform. Today Capital Cell has formally ‘opened to investors’ with the first four investment opportunities now live on the platform.
20 September 2017Read in full
Capital Cell, Europe’s first equity crowdfunding platform specialised in life science, has been shortlisted for the prestigious 'Best International Growth Business' award at the UK Business Angels Association Investment Awards 2017.
23 June 2017Read in full